



Prescription Drug Coverage Determination Form
Tumor Necrosis Factor Inhibitor
Humira® (adalimumab)

Please fax the completed form to Mercy Health Plans' Pharmacy Department at 314-214-8201 or 1-800-647-2240.

Patient Information

Patient Name: Date of Birth:
Subscriber ID#:
Address City State Zip Code

Physician Information

Name: Specialty: Tax ID#:
Office Address City State Zip Code
Telephone: Fax: Contact Person

Physician Signature (REQUIRED): Date

Medication Information (requests for non-formulary agents will be considered for members having a documented failure or contraindication to preferred agents.)

Medication name: J-code:
Dose: Directions:
Expected Duration of Therapy:

Prior Authorization Criteria:

Does the patient have any of the following diagnosis:

- 1. Moderately to severely active rheumatoid arthritis?
If yes:
- Is the patient 18 years of age or older?
- Has the patient demonstrated an inadequate response to at least 1 disease-modifying anti-rheumatoid drug (DMARD) [e.g., methotrexate (MTX), Imuran (azathioprine), Ridaura (oral gold), Plaquenil (hydroxychloroquine), Cuprimine (D-penicillamine), Azulfidine (sulfasalazine), or Arava (leflunomide)] or intolerance to multiple DMARDs?
2. Moderately to severely active polyarticular (with multiple joint involvement) juvenile idiopathic arthritis (JRA)?
If yes:
- Has the patient demonstrated an inadequate response to at least 1 disease-modifying anti-rheumatoid drug [e.g. methotrexate (MTX), Imuran (azathioprine), Plaquenil (hydroxychloroquine), Cuprimine (D-penicillamine), Azulfidine (sulfasalazine), or Arava (leflunomide)] or intolerance to multiple DMARDs?

3. Active psoriatic arthritis?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
If yes:		
▪ Is the patient 18 years of age or older?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
4. Active ankylosing spondylitis?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
If yes:		
▪ Is the patient 18 years of age or older?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
▪ Has the patient had an inadequate response to at least 2 non-steroidal anti-inflammatory (NSAID) drugs or intolerance to multiple NSAIDs?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
▪ Is the ankylosing spondylitis predominately peripheral arthritis?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
▪ Has the patient demonstrated an inadequate response, intolerance to, or contraindication to sulfasalazine?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
5. Moderately to severely active Crohn's disease?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
If yes:		
▪ Is the patient 18 years of age or older?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
▪ Has the patient demonstrated an inadequate response to conventional therapy for Crohn's disease (i.e., prednisone, budesonide, sulfasalazine (Azulfidine), azathioprine (Imuran), mesalamine (Asacol or Pentasa) or infliximab (Remicade))?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
6. Plaque psoriasis?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
If yes:		
▪ Is the patient 18 years of age or older?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
▪ Is the patient a candidate for systemic therapy or phototherapy?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
7. Was the patient evaluated for latent tuberculosis infection with a PPD tuberculin test?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
If yes:		
▪ Did the patient have a positive PPD tuberculin test?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
▪ If yes, is the patient being treated for latent tuberculosis?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
8. Does the patient have an active infection, including chronic and localized infections?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
9. Is the patient receiving a biologic response modifier, either a tumor necrosis factor (TNF) blocking agent [e.g., Humira, Remicade] or an interleukin-1 receptor antagonist (IL1-Ra) [e.g., Kineret] other than Enbrel?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
If yes:		
▪ Will the biologic response modifier be discontinued?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
10. Has the patient been assessed for risk of active hepatitis B infection?	<input type="checkbox"/> Yes	<input type="checkbox"/> No

Please provide any additional history or medical information that may support coverage (attach office notes as necessary): \_\_\_\_\_

Note: If approved coverage will be as specified in above criteria or through the end of the year (December 31, 20xx). Some medications may be subject to quantity limitations or restricted to certain pharmacies.